Cite
HARVARD Citation
Eng, C. et al. (2019). Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet oncology. 20 (6), pp. 849-861. [Online].